Shanghai Pharmaceuticals Holding Co., Ltd.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
1
Ending by 2030
Jun 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 9, 2027The maintenance fee for Salt of quinolone compound, polymorphs thereof, preparation method therefor, composition, and applications (US 10,344,035) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due Jun 30, 2027The maintenance fee for Salts of morpholine derivative, crystal forms thereof, processes for producing the same, pharmaceutical compositions including the same, and use thereof (US 10,519,150) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Sep 8, 2027The maintenance fee for Nitrogen-containing saturated heterocyclic compound (US 9,278,944) comes due Sep 8, 2027. Unpaid by Mar 8, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Nov 3 US 12,780,822 Crystalline Form of Nitrogen-Containing Heterocyclic Compound, Preparation Method Therefor and Use Thereof
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,975,252 | Morpholine Derivative In force · High confidence | In force | High confidence | |
| US 9,278,944 | Nitrogen-containing saturated heterocyclic compound In force · USPTO record | In force | USPTO record | |
| US 10,155,731 | Nitrogen-Containing Saturated Heterocyclic Compound In force · Low confidence | In force | Low confidence | |
| US 9,556,159 | Renin inhibitor In force · USPTO record | In force | USPTO record | |
| US 10,344,035 | Salt of quinolone compound, polymorphs thereof, preparation method therefor, composition, and applications In force · USPTO record | In force | USPTO record | |
| US 10,519,150 | Salts of morpholine derivative, crystal forms thereof, processes for producing the same, pharmaceutical compositions including the same, and use thereof In force · USPTO record | In force | USPTO record | |
| US 11,578,074 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application In force · USPTO record | In force | USPTO record | |
| US 11,643,428 | Therapeutic Drug for Neurodegenerative Disease and Application Thereof In force · High confidence | In force | High confidence | |
| US 11,578,092 | Novel Compound for Preventing or Treating Neurodegenerative Disease and Application Thereof In force · High confidence | In force | High confidence | |
| US 12,612,408 | Pyrazolone-Fused Pyrimidine Compound, Preparation Method for Same and Applications Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 1 patent in force now held by others · 4 lapsed for an unpaid fee · 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 4 abandoned · 9 no status recorded